Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideki Goto

Showing results (41-50 of 95) with videos related to

Pageof 10
Sort By:
International Journal of Clinical Oncology|September 2, 2025
Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphomaHideki Goto, Satoshi Ito, Masahiro Kizaki, et al.
British Journal of Haematology|April 26, 2007
Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantationMitsufumi Nishio, Katsuya Fujimoto, Satoshi Yamamoto, et al.
Annals of Hematology|January 31, 2018
A novel heterozygous ITGB3 p.T720del inducing spontaneous activation of integrin αIIbβ3 in autosomal dominant macrothrombocytopenia with aggregation dysfunctionNaohiro Miyashita, Masahiro Onozawa, Koji Hayasaka, et al.
International Journal of Hematology|August 23, 2024
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II studyKoji Izutsu, Kiyoshi Ando, Momoko Nishikori, et al.
Internal Medicine (Tokyo, Japan)|June 14, 2023
Type 1 Cryoglobulinemic Vasculitis Due to Monoclonal Gammopathy of Undetermined Significance Successfully Treated by Bortezomib Plus DexamethasoneRyo Kikuchi, Masahiro Onozawa, Jun Nagai, et al.
International Journal of Hematology|April 28, 2016
Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHDToshihiro Matsukawa, Daigo Hashimoto, Junichi Sugita, et al.
Clinical Transplantation|July 29, 2018
The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantationDaisuke Hidaka, Eiko Hayase, Souichi Shiratori, et al.
Leukemia|July 13, 2026
PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activationYuto Mori, Keito Suto, Norio Takei, et al.
Cytotherapy|May 16, 2025
Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trialKoji Kato, Jun Kato, Hideki Goto, et al.
International Journal of Clinical Oncology|December 29, 2023
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphomaHideki Goto, Satoshi Ito, Masahiro Kizaki, et al.
Pageof 10

Showing results (41-50 of 95) with videos related to

Sort By:
Pageof 10
International Journal of Clinical Oncology|September 2, 2025
Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphomaHideki Goto, Satoshi Ito, Masahiro Kizaki, et al.
British Journal of Haematology|April 26, 2007
Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantationMitsufumi Nishio, Katsuya Fujimoto, Satoshi Yamamoto, et al.
Annals of Hematology|January 31, 2018
A novel heterozygous ITGB3 p.T720del inducing spontaneous activation of integrin αIIbβ3 in autosomal dominant macrothrombocytopenia with aggregation dysfunctionNaohiro Miyashita, Masahiro Onozawa, Koji Hayasaka, et al.
International Journal of Hematology|August 23, 2024
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II studyKoji Izutsu, Kiyoshi Ando, Momoko Nishikori, et al.
Internal Medicine (Tokyo, Japan)|June 14, 2023
Type 1 Cryoglobulinemic Vasculitis Due to Monoclonal Gammopathy of Undetermined Significance Successfully Treated by Bortezomib Plus DexamethasoneRyo Kikuchi, Masahiro Onozawa, Jun Nagai, et al.
International Journal of Hematology|April 28, 2016
Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHDToshihiro Matsukawa, Daigo Hashimoto, Junichi Sugita, et al.
Clinical Transplantation|July 29, 2018
The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantationDaisuke Hidaka, Eiko Hayase, Souichi Shiratori, et al.
Leukemia|July 13, 2026
PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activationYuto Mori, Keito Suto, Norio Takei, et al.
Cytotherapy|May 16, 2025
Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trialKoji Kato, Jun Kato, Hideki Goto, et al.
International Journal of Clinical Oncology|December 29, 2023
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphomaHideki Goto, Satoshi Ito, Masahiro Kizaki, et al.
Pageof 10